These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 28481440)

  • 1. Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance.
    Tosoian JJ; Chappidi MR; Bishoff JT; Freedland SJ; Reid J; Brawer M; Stone S; Schlomm T; Ross AE
    BJU Int; 2017 Dec; 120(6):808-814. PubMed ID: 28481440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell cycle progression score improves risk stratification in prostate cancer patients with adverse pathology after radical prostatectomy.
    Shangguan X; Qian H; Jiang Z; Xin Z; Pan J; Dong B; Xue W
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):687-694. PubMed ID: 31745702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.
    Cooperberg MR; Simko JP; Cowan JE; Reid JE; Djalilvand A; Bhatnagar S; Gutin A; Lanchbury JS; Swanson GP; Stone S; Carroll PR
    J Clin Oncol; 2013 Apr; 31(11):1428-34. PubMed ID: 23460710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy.
    Canter DJ; Freedland S; Rajamani S; Latsis M; Variano M; Halat S; Tward J; Cohen T; Stone S; Schlomm T; Bishoff J; Bardot S
    Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):102-107. PubMed ID: 31243337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy.
    Bishoff JT; Freedland SJ; Gerber L; Tennstedt P; Reid J; Welbourn W; Graefen M; Sangale Z; Tikishvili E; Park J; Younus A; Gutin A; Lanchbury JS; Sauter G; Brawer M; Stone S; Schlomm T
    J Urol; 2014 Aug; 192(2):409-14. PubMed ID: 24508632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
    Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
    Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
    Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
    Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
    Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
    Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer.
    Morris DS; Woods JS; Edwards B; Lenz L; Logan J; Flake DD; Mabey B; Bishoff JT; Cohen T; Stone S
    Urol Oncol; 2021 Jun; 39(6):366.e19-366.e28. PubMed ID: 33257218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
    Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
    Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of biochemical recurrence-free survival after radical prostatectomy by cancer of the prostate risk assessment post-surgical (CAPRA-S) score.
    Aktas BK; Ozden C; Bulut S; Tagci S; Erbay G; Gokkaya CS; Baykam MM; Memis A
    Asian Pac J Cancer Prev; 2015; 16(6):2527-30. PubMed ID: 25824791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stratification of patients with intermediate-risk prostate cancer.
    Jung JW; Lee JK; Hong SK; Byun SS; Lee SE
    BJU Int; 2015 Jun; 115(6):907-12. PubMed ID: 24612460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy.
    Léon P; Cancel-Tassin G; Drouin S; Audouin M; Varinot J; Comperat E; Cathelineau X; Rozet F; Vaessens C; Stone S; Reid J; Sangale Z; Korman P; Rouprêt M; Fromond-Hankard G; Cussenot O
    World J Urol; 2018 Sep; 36(9):1495-1500. PubMed ID: 29679140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology.
    Athanasiou A; Tennstedt P; Wittig A; Huber R; Straub O; Schiess R; Steuber T
    PLoS One; 2021; 16(11):e0259093. PubMed ID: 34767586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
    Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
    J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy.
    Freedland SJ; Gerber L; Reid J; Welbourn W; Tikishvili E; Park J; Younus A; Gutin A; Sangale Z; Lanchbury JS; Salama JK; Stone S
    Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):848-53. PubMed ID: 23755923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National Comprehensive Cancer Network (NCCN) risk classification in predicting biochemical recurrence after radical prostatectomy: a retrospective cohort study in Chinese prostate cancer patients.
    Xu H; Zhu Y; Dai B; Ye DW
    Asian J Androl; 2018; 20(6):551-554. PubMed ID: 30027928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    Eur Urol; 2017 Jun; 71(6):907-912. PubMed ID: 27876305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.